ArticleCureus2022
Primary Extrapulmonary Rifampicin Mono-Resistant Tuberculosis of the Parotid Gland in an Indian Female: The World's First Case.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis at extrapulmonary sites is relatively uncommon. A case of isolated involvement of the salivary gland is even rare and primary rifampicin mono-resistant tuberculosis of the parotid gland is rarest of rare with no such report ever documented in the medical literature. In this case report, the author presents a case of primary extrapulmonary rifampicin mono-resistant tuberculosis of the parotid gland in a 44-year-old Indian female. She presented with complaints of a painless swelling in the right parotid region and underwent a detailed diagnostic work-up including fine needle aspiration cytology, cartridge-based nucleic acid amplification test, computed tomography scan of head and neck, and culture, and was diagnosed with primary extrapulmonary rifampicin mono-resistant tuberculosis of the parotid gland. The patient was initiated on a WHO-recommended regimen per the national guidelines. After nine months of treatment, she had no symptoms and was declared as treatment completed. With no such case ever reported, this case emphasizes the importance of a high degree of suspicion for rare presentations of common diseases like tuberculosis even in the absence of a history, contacts, or other constitutional symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.